Travelan has a whole lot of value if it indeed works as a Shigella vaccine.
I also agree with Whittpa that Big Pharma will want to do a deal. What we don't know are management's expectations of what is fair. We also don't know if they are looking for a straight buyout or a partnership. Regardless, the company burns very little cash and, with NIH paying for the ASH and PNAFLD trials, we have over a year's worth of cash at least so Immuron won't be diluting anytime soon.
In six to eight months, the landscape will look very different with 3 more Phase 2 trial results in (ASH, NAFLD, C.DIFF). Remember, Tobira for example sold for $1.7B when it was trading at an $85M market cap. We don't know what management's expectations are. Maybe as we speak today they would turn down say a $200M USD offer for the company because they think it's far too low. That's a distinct possibility.
Only time will tell. Happy to wait and see this through
